Genomtec Past Earnings Performance

Past criteria checks 0/6

Genomtec has been growing earnings at an average annual rate of 0.2%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 104.3% per year.

Key information

0.2%

Earnings growth rate

14.8%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate-104.3%
Return on equity-122.1%
Net Margin-1,157,600.0%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Genomtec makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:4VI Revenue, expenses and earnings (PLN Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-12110
30 Jun 240-11110
31 Mar 240-10100
31 Dec 230-990
30 Sep 230-13100
30 Jun 230-1290
31 Mar 230-1390
31 Dec 220-1290
30 Sep 220-860
30 Jun 220-760
31 Mar 220-650
31 Dec 210-750
30 Sep 210-14120
30 Jun 210-14120
31 Mar 210-12120
31 Dec 200-11110

Quality Earnings: 4VI is currently unprofitable.

Growing Profit Margin: 4VI is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 4VI is unprofitable, but has reduced losses over the past 5 years at a rate of 0.2% per year.

Accelerating Growth: Unable to compare 4VI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 4VI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).


Return on Equity

High ROE: 4VI has a negative Return on Equity (-122.08%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 05:07
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Genomtec S.A. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution